One third of retroperitoneal postchemotherapy lesions

No abstract

No abstract

T1-weighted and STIR images obtained during and soon after radiation therapy complement each other in showing changes in bone marrow.

Postchemotherapy RLND can be omitted in patients with MTU in the primary tumor who have normal AFP/human chorionic gonadotropin (AFP/HCG) before chemotherapy and whose residual retroperitoneal mass is less than 20 mm in diameter. If the pre-RLND tumor markers are normal, RLND should be performed in all other patients with small residual masses, even in the presence of a normal computed tomography (CT) and particularly if regular follow-up of the patients is not guaranteed.